Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Daphne A Stanley¹, Anna N Honko², Clement Asiedu³, John C Trefry⁴, Annie W Lau-Kilby¹, Joshua C Johnson², Lisa Hensley², Virginia Ammendola⁵, Adele Abbate⁵, Fabiana Grazioli⁵, Kathryn E Foulds¹, Cheng Cheng¹, Lingshu Wang¹, Mitzi M Donaldson¹, Stefano Colloca⁵, Antonella Folgori⁵, Mario Roederer¹, Gary J Nabel⁶, John Mascola¹, Alfredo Nicosia⁷, Riccardo Cortese⁸, Richard A Koup¹, Nancy J Sullivan¹

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
² 1] United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA. [2] Integrated Research Facility, NIAID, NIH, Fort Detrick, Maryland, USA (A.N.H., J.C.J. and L.H.), and Sanofi, Cambridge, Massachusetts, USA (G.J.N.).
³ 1] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA. [2].
⁴ United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
⁵ Okairos, Rome, Italy.
⁶ 1] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA. [2] Integrated Research Facility, NIAID, NIH, Fort Detrick, Maryland, USA (A.N.H., J.C.J. and L.H.), and Sanofi, Cambridge, Massachusetts, USA (G.J.N.).
⁷ 1] Okairos, Rome, Italy. [2] Centro Ingegneria Genetica (CEINGE), Naples, Italy. [3] Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
⁸ Keires AG, Basel, Switzerland.

PMID: 25194571
DOI: 10.1038/nm.3702

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Daphne A Stanley et al. Nat Med. 2014 Oct.

. 2014 Oct;20(10):1126-9.

doi: 10.1038/nm.3702. Epub 2014 Sep 7.

Authors

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
² 1] United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA. [2] Integrated Research Facility, NIAID, NIH, Fort Detrick, Maryland, USA (A.N.H., J.C.J. and L.H.), and Sanofi, Cambridge, Massachusetts, USA (G.J.N.).
³ 1] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA. [2].
⁴ United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
⁵ Okairos, Rome, Italy.
⁶ 1] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA. [2] Integrated Research Facility, NIAID, NIH, Fort Detrick, Maryland, USA (A.N.H., J.C.J. and L.H.), and Sanofi, Cambridge, Massachusetts, USA (G.J.N.).
⁷ 1] Okairos, Rome, Italy. [2] Centro Ingegneria Genetica (CEINGE), Naples, Italy. [3] Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
⁸ Keires AG, Basel, Switzerland.

PMID: 25194571
DOI: 10.1038/nm.3702

Abstract

Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.

PubMed Disclaimer

References

1. Virology. 2006 Mar 15;346(2):394-401 - PubMed
1. Mol Ther. 2012 Dec;20(12):2355-68 - PubMed
1. PLoS Pathog. 2010 May 20;6(5):e1000904 - PubMed
1. PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2171 - PubMed
1. Nat Rev Immunol. 2008 Apr;8(4):247-58 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Affiliations

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical